Publisher
Kitakanto Medical Society
Reference8 articles.
1. 1. J von Pawel, R Jotte, DR Spigel, ME, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 2014; 32: 4012-4019.
2. 2. Bartlett JM, McConkey CC, Munro AF, et al. Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also. J Clin Oncol 2015; 33: 1680-1687.
3. 3. Miura Y, Kaira K, Sunaga N, Saito R, Hisada T, Yamada M, et al. High expression of topoisomerase-II predicts favorable clinical outcomes in patients with relapsed small cell lung cancers receiving amrubicin. Lung Cancer 2018; 115: 42-48.
4. 4. Dingemans AM, Witlox MA, Stallaert RA, et al. Expression of DNA topoisomerase II alpha and topoisomerase II beta genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin Cancer Res 1999; 5: 2048-2058.
5. 5. Karachaliou N, Papadaki C, Lagoudaki E, et al. Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPOmicron-IIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposide. PLoS One 2013; 8: e74611.